Digital Breast Tomosynthesis: What We now Know Beyond the Prevalent Screen

Abstract Digital breast tomosynthesis (DBT) entered the clinical arena in the early 2010s, and initial studies reported encouraging outcomes such as higher cancer detection rates and reduced recall rates. It is important to recognize that when new technologies like DBT are introduced as screening tools, however, their first (prevalent) screens typically detect more cancers than prior methods, known as a prevalence effect. Thus, assessment of multiple rounds of re-screening is necessary to further define DBT’s role in population screening and its impact on interval cancer rates and detection of advanced cancers. This article aims to describe what we are learning about DBT beyond the prevalent screening round.